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Abstract
Purpose: Multidrug resistance is one of the main impediments to the successful treatment of colon cancer.
Glucosylceramide synthase (GCS) which is related to multidrug resistance (MDR) can reduce the level of ceramide
and can help cells escape from the ceramide-induced cell apoptosis. However, the underlying mechanism is still
unclear.
Methods: The cell proliferation and cell toxicity were measured with Cell Counting Kit-8 (CCK-8). The mRNA levels
of GCS and MDR1 were detected by semiquantitative reverse transcription-PCR amplification, the protein levels of
GCS, caspase-3 and P-gp proteins were indicated by Western blotting. The apoptosis rates of cells were measured
with flow cytometry.
Results: The relative mRNA levels of GCS in HCT-8, HCT-8/VCR, HCT-8/VCR- sh-mock and HCT-8/VCR-sh-GCS were
71.4 ± 1.1%, 95.1 ± 1.2%, 98.2 ± 1.5%, and 66.6 ± 2.1% respectively. The mRNA levels of MDR1 were respectively
61.3 ± 1.1%, 90.5 ± 1.4%, 97.6 ± 2.2% and 56.1 ± 1.2%. The IC50 of Cisplatin complexes were respectively 69.070 ±
0.253 μg/ml, 312.050 ± 1.46 μg/ml, 328.741 ± 5.648 μg/ml, 150.792 ± 0.967 μg/ml in HCT-8, HCT-8/VCR, HCT-8/VCR-
sh-mock and HCT-8/VCR-sh-GCS. The protein levels of caspase-3 were 34.2 ± o.6%, 93.0 ± 0.7%, 109.09 ± 0.7%, 42.7
± 1.3% respectively. The apoptosis rates of cells were 8.77 ± 0.14%, 12.75 ± 0.54%, 15.39 ± 0.41% and 8.49 ± 0.23%
respectively.
Conclusion: In conclusion, our research indicated that suppression of GCS restores the sensitivity of multidrug
resistance colon cancer cells to drug treatment.
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Background
Multidrug resistance (MDR) is one of the main impedi-
ments to the successful treatment of colon cancer [1].
Furthermore, colorectal tumors which obtain resistance
to one drug are often resistant to several other drugs as
well [2]. The underlying mechanisms are complicated
[3]. One reason for MDR relates to P-glycoprotein (P-
gp) and other transporters which are expressed in some
cancer cells and could strengthen the efflux of diverse
chemotherapeutic agents from cells [2]. Elevated levels
of these MDR proteins, which belong to the ATP-bind-
ing cassette (ABC) transporter family, strengthen cellular
efflux and reduce the effectiveness of anticancer drugs
[4]. One method to measure P-glycoprotein efflux has
been set up to o determine tumor response to che-
motherapy [1]. To conquer drug resistance, inhibitors of
MDR proteins have been developed, however their non-
specific inhibition has brought side effects.
Glucosylceramide (GCS) can reduce the level of cera-
mide and allows cellular escape from ceramide-induced
cell apoptosis, which has been deemed to be related
with MDR [5]. More recently, it has been demonstrated
that the expression of the GCS gene in drug-resistant
K562/AO2 human leukemia cells was higher than that
in drug-sensitive K562 cells, and the sensitivity of K562/
AO2 cells to adriamycin was enhanced by GCS inhibi-
tion [6].
The mechanisms mediating drug resistance include
defective apoptotic signaling and overexpression of anti-
apoptotic proteins, which regulate apoptotic cell death
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the sensitivity of tumor cells to chemotherapy [7]. High
level expression of Bcl-2 is found in many human hema-
tologic malignancies and solid tumors [8,9]. The down-
regulation of Bcl-2 or other anti-apoptotic proteins,
such as Bcl-xL, could either induce apoptosis in cancer
cells or could sensitize these cells for chemotherapy
[10,11]. In addition, these proteins protect drug-resistant
tumor cells from multiple forms of caspase-dependent
apoptosis [12,13]. Moreover, functional P-gp can inhibit
the activation of caspase-3 and-8 by some apoptotic sti-
muli [14,15].
Based on the above, we speculate that suppression of
GCS by the stable transfection of UGCG shRNA Plas-
mid would restore sensitivity of multidrug resistance
colon cancer cells by the stable transfection of UGCG
shRNA Plasmid.
Methods
Cell lines and cell culture
The colon cancer cell line HCT-8 was purchased from
ATCC, and the cell line HCT-8/VCR was purchased
from Xiangya Central Experiment Laboratory (Hunan,
China). The cells were cultured at 37°C in RPMI-1640
culture medium (Hyclone) in humidified atmosphere
containing 5% CO2, with the medium for HCT-8 cells
containing 10% FBS, and with the medium for HCT-8/
VCR cells containing 10% FBS and 2 μg/ml vincristine.
All experiments were performed according to the guide-
lines approval by The ethical committee of Zhengzhou
University(NO.20120066).
Stable transfection of cells
UGCG shRNA Plasmid (h) was purchased from Santa
Cruz. UGCG shRNA Plasmid (h) is recommended for
the inhibition of glucosylceramide synthase expression
in human cells, which is a pool of 3 target-specific lenti-
viral vector plasmids encoding 19-25 nt (plus hairpin)
shRNAs designed to knock down gene expression.
HCT-8 cells were seeded in 6-well plate with antibiotic
free medium. After 24 h incubation, the mixture of
transfection regent and ShRNA were incubated with
cells according to the manufacturer’s instructions. These
cells were incubated for an additional 18-24 hours
under normal culture conditions. 48 h after transfection,
the medium was aspirated and replaced with fresh med-
ium containing 100 μg/ml puromycin. The medium was
changed every 3 days. The following experiments were
performed after 20 days of culture.
Semi- quantitative reverse transcription-PCR analysis
Total RNA was extracted from cells by using TRIquick
Reagent (solarbio). The mRNA levels of GCS and
MDR1 were measured with RT-PCR. The following
specific oligonucleotide primers were designed respec-
tively for mdr1 (mdr1-F:5’- TGGTGGTGGGAACTT
TGG-3’ and mdr1-R:5’-CCTATCTCCTGTCGCATT-3’),
GCS (GCS-F:5’-CACCCGATTACACCTCAA - 3’ and
GCS-R: 5’-CCGTGAACC AAGCCTACT-3’), b-actin (b-
actin-F:5’-TGACGTGGACATC CGCAAAG - 3’,a n db-
actin-R: 5’-CTGGAA GGTGGACAGCGAGG - 3’). PCR
cycles were adjusted to have linear amplification for all
the targets. Each RT-PCR reaction was repeated three
times. The semiquantitative analysis of GCS mRNA and
MDR1 mRNA levels was measured with Syngene Gel
Imaging System and analysis software (Syngene
Company).
Western blotting analysis of P-gp, Caspase-3 and GCS
protein
HCT-8, HCT-8/VCR, HCT-8/VCR-sh-mock and HCT-
8/VCR-sh-GCS were harvested using RIPA cell lysis buf-
fer (Biotech Corporation). The protein concentrations
were measured by using a bicinchoninic acid (BCA) pro-
tein assay kit. Equal aliquots of total detergent-soluble
proteins (50 μg) were resolved to 5-10% gradient SDS-
PAGE. The transferred PVDF membrane were blocked
with 5% fat-free milk in TBST at room temperature for 1
h and then incubated with primary antibodies (anti-P-gp
antibody, C-19, anti-GCS antibody, anti-caspase-3 or
anti-b-actin antibody; 1:1000 dilution) at 4°C overnight.
The protein was detected by using horseradish peroxi-
dase (HRP) and enzyme-linked chemiluminescence
(ECL) plus substrate (GE Healthcare, Piscataway, NJ)
Anti-human P-gp antibody (C-19) and GCS antibody (H-
300) and anti-caspase-3 antibody were purchased from
Santa Cruz Corporation. The protein levels of P-gp, Cas-
pase-3 and GCS were represented by the ratios of optical
densities in their bands normalized against b-actin.
Cytotoxicity assay
In 96 well plates, cells were seeded in 100 μl PRMI-1640
medium supplemented with 10% FBS at 5 × 10
3 cells/
well. Then chemotherapeutic agents were added in nor-
mal growth medium supplemented with FBS. After 48 h
incubation, 10 μlC e l lC o u n t i n gK i t - 8( C C K - 8 )w a s
added and culture was continued for 1 h in humidified
atmosphere containing 5% CO2. Absorbances at 450 nm
were measured by Microplate Reader (Bio-Tech Com-
pany). The relative drug resistance folds were analyzed
by compared with IC50.
Flow cytometry
To measure the apoptosis rate of the cells, we chose the
AnnexinV-FITC Apoptosis Detection Kit. The cells were
washed 2 times by 4°CPBS, and diluted with 400 μl
AnnexinV binding liquid, then added 5 μlA n n e x i nV -
FITC at 4°C for 15 min without light, and then added
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measure with flow cytometry within 1 h.
Statistical analysis
All of the data were presented as the mean ± SD, and
analyzed with one-way ANOVA by SPSS16.0 software
package.
Results
mRNA levels of GCS and MDR1 decreased in the cells
stable transfected with UGCG shRNA Plasmid (h)
To check the knockdown effect of UGCG shRNA, the
mRNA levels of GCS and MDR1 were measured with
semiquantitative reverse transcription-PCR amplification.
The length of the PCR products were 331 bp (MDR1),
4 1 4b p( G C S )a n d2 0 5b p( b-actin) respectively. As
shown in Figure 1A, the relative mRNA levels of GCS in
HCT-8, HCT-8/VCR, HCT-8/VCR-sh-mock and HCT-
8/VCR-sh-GCS were 71.4 ± 1.1%, 95.1 ± 1.2%, 98.2 ±
1.5%, and 66.6 ± 2.1% respectively. The mRNA levels of
MDR1 were respectively 61.3 ± 1.1%, 90.5 ± 1.4%, 97.6.8
± 2.2% and 56.1 ± 1.2%.
P-gp protein level decreased when knocking down GCS in
HCT-8/VCR cells
The protein levels of GCS and P-gp in stable cell lines
were detected by Western-blotting. As indicated in Fig-
u r e1 B ,t h ep r o t e i nl e v e lo f GCS increased in HCT-8/
VCR, HCT-8/VCR-sh-mock cells compared to HCT-8
cells. The protein levels of GCS in HCT-8/VCR-sh-GCS
Figure 1 Knocking down GCS inhibits mRNA expression of MDR1 and protein level of P-pg. A, the mRNA level are higher in HCT-8/VCR
cells compared with HCT-8 cells. The GCS mRNA level decreased when transfected with shGCS plasmids. The MDR1 gene expressin increased in HCT-
8/VCR cells compared with HCT-8 cells. The MDR1 mRNA level also decreased when knocking down GCS. B, the protein level of P-pg decreased when
knocking down GCS. Protein level of b-actin was set as 100%. *Ρ < 0.01 compared with the HCT-8/VCR and HCT-8/VCR-sh-mock cells.
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also true for protein level of P-pg.
Knocking down GCS suppressed HCT-8/VCR proliferation
The proliferation of HCT-8, HCT-8/VCR, HCT-8/VCR-
sh-mock and HCT-8/VCR-sh-GCS cells was detected by
Cell Counting Kit-8 (CCK-8). We measured the growth
of the cells every 24 h, for 4 days. Knowing down GCS
impaired HCT-8/VCR-sh-GCS cell proliferation (Ρ <
0.05) (Figure 2).
Knocking down GCS in HCT-8/VCR cells reverse its
sensitive to cisplatin treatment
Cisplatin is one of the effective chemotherapeutic agents
in clinical cancer treatment. It was found here that the
IC50 of Cis-platinum complexes were respectively
69.070 ± 0.253 μg/ml, 312.050 ± 1.46 μg/ml, 328.741 ±
5.648 μg/ml, 150.792 ± 0.967 μg/ml in HCT-8, HCT-8/
VCR, HCT-8/VCR-sh-mock and HCT-8/VCR-sh-GCS.
The drug resistance folds were respectively 4.6 (HCT-8/
VCR), 4.7(HCT-8/VCR-sh-mock), 2.2(HCT-8/VCR-sh-
GCS), the sensitive cells HCT-8 was set as 1(Figure 3).
Knocking down GCS positively related with caspase-3
protein level in HCT-8/VCR cells
The downregulation of Bcl-2 or other antiapoptotic pro-
teins could either induce apoptosis in cancer cells or
sensitize these cells to chemotherapy [10,11]. Moreover,
functional P-gp inhibits the activation of caspase-3 by
some apoptotic stimuli [14,15]. We measured the pro-
tein levels of caspase-3 in HCT-8, HCT-8/VCR, HCT-8/
VCR-sh-mock and HCT-8/VCR-sh-GCS cells. As shown
in Figure 4 the relative expression levels of caspase-3
were respectively 34.2 ± 0.6%, 93.0 ± 0.7%, 109.09 ±
0.7%, 42.7 ± 1.3%.
HCT-8/VCR cells apoptosis decreased in GCS knockdown
HCT-8/VCR cells
The mechanisms mediating drug resistance include
defective apoptotic signaling that regulate apoptotic cell
death playing an important role in determining the sen-
sitivity of tumor cells to chemotherapy [7]. We mea-
sured the apoptosis rates of cells by flow cytometry. The
rates were shown in Figure 5, it demonstrated that the
rates were 8.77 ± 0.14%, 12.75 ± 0.54%, 15.39 ± 0.41%
and 8.49 ± 0.23%. By further analysis, there were differ-
ences in HCT-8, and HCT-8/VCR compared to HCT-8/
VCR-sh-mock and HCT-8/VCR-sh-GCS(Ρ <0 . 0 1 ) .
There were differences between HCT-8/VCR-sh -mock
and HCT-8/VCR-sh-GCS (Ρ < 0.01).
Discussion
Multidrug resistance is one of the main obstacles to the
successful treatment in patients with colon cancer, and
the underlying mechanisms are complex [1]. It is known
that P-glycoprotein (P-gp), the drug efflux protein, and
inhibitors of apoptosis proteins (IAPs) are involved in
the MDR of leukemic cells [16]. Recently research has
indicated that overexpression of P-gp and cIAP may
enhance the infiltration of leukemic cells [16]. Lavie et
al. revealed that chemotherapy resistant MCF-7-AdrR
breast cancer cells accumulate GC compared to wild-
Figure 2 Knocking down GCS suppresses HCT-8/VCR cell
proliferation. HCT-8 cell (2 × 10
3) were seeded in 96-well in 100 ul
PRMI-1640 medium. Cell proliferation was determined at 24-h
intervals up to 96 h in sh-mock or sh-GCS stably transfected cells.
Data are shown as means ± S.D.
Figure 3 Knocking down GCS causes HCT-8/VCR more sensitive
to cisplatin induced cell death. HCT-8, HCT-8/VCR, HCT-8/VCR sh-
mock or sh-GCS stably transfected cells (5 × 10
3) were seeded in
96-well in 100 ul PRMI-1640 medium. Cells were treated with
different concentaration of cisplatin for 48 h. The relative drug
resistance folds were analyzed by compared with IC50. The cell
survival rate of cells without cisplatin complexes was set as 100%. *Ρ
< 0.01 compared with the HCT-8/VCR and HCT-8/VCR-sh-mock cells.
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found to confer MDR in many other cancers [18-20].
The level of protein P-gp in MCF-7-AdrR is higher than
that in MCF-7. The GCS expression in these two cell
lines has the same pattern. These phenomena give us
the clue that these two proteins are closely related. The
high expression of GCS in the same cell lines shows us
that there may be some relation between P-gp and GCS.
Our results indicated that the mRNA level of GCS in
HCT-8/VCR was higher than that in HCT-8, and its
level decreased when the HCT-8/VCR were transfected
with UGCG shRNA Plasmid. The expression level of
MDR1 mRNA was also in the same pattern. This result
indicated these two proteins have some relations. This
result is consistent with the recently published work by
liu et al. [21]. We also found that the protein level of
caspase-3 was higher in insensitive cells than in sensitive
cells.
Our research also found that the expression of GCS
protein was much higher in HCT-8/VCR than that in
HCT-8. And so was the protein level of P-gp. When the
HCT-8/VCR was transfected with UGCG shRNA Plas-
mid, the protein levels of GCS and P-gp were decreased.
The results indicated that there may be a relation
between GCS and P-gp proteins.
Cytotoxity results demonstrated that HCT-8/VCR
needs a much higher drug concentration to get 50%
inhibition of cell growth. The needed drug concentra-
tion decreased when HCT-8/VCR was transfected with
UGCG shRNA Plasmid. This result indicated that drug
resistance in HCT-8/VCR was reversed. The higher level
of the apoptotic gene in the insensitive cells may
Figure 4 Knocking down GCS affects Caspase-3 protein level.
The Caspase-3 protein level decreased when transfected with
shGCS plasmids.
Figure 5 Knocking down GCS affects HCT-8/VCR cells
apoptosis. The apoptosis of HCT-8, HCT-8/VCR, HCT-8/VCR sh-mock
or sh-GCS stably transfected cells were measured with flow
cytometry (A, HCT-8, B, HCT-8/VCR, C, HCT-8/VCR-sh-mock and D,
HCT-8/VCR-sh-GCS).
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apoptosis, the cells with high level GCS may be better
able to adapt to the new circumstances, while the sensi-
tive cells may not. The apoptosis rate was higher in
insensitive cells than sensitive cells. The result is differ-
ent with the other researchers. The reason may be the
coactions of many apoptotic and anti-apoptotic proteins.
In conclusion, our research demonstrated that GCS
play an important role in multidrug resistance mechan-
isms of colon cancer cells with high expression of GCS
gene. The up-regulation of GCS could affect the expres-
sion of MDR1 in colon cancer cells. They may coop-
erate with each other in the formation of multidrug
resistance.
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